Circassia Pharmaceuticals PLC

Circassia sets platform for strong growth in 2019 after period of consolidation

Steve Harris, chief executive of Circassia Pharmaceuticals PLC (LON:CIR), talks Proactive London's Andrew Scott through the group's 2018 results and the first quarter of this year.

Circassia's taken full commercial control of Tudorza, a treatment for chronic obstructive pulmonary disease (COPD), while its sales of its asthma product NIOX continued to grow.

They've also added AirNOvent, a late-stage nitric oxide candidate, to its pipeline, which, when approved, should aid the sales effort.

Quick facts: Circassia Pharmaceuticals PLC

Price: £0.18

Market: LSE
Market Cap: £66.78 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Circassia Pharmaceuticals PLC named herein, including the promotion by the Company of Circassia Pharmaceuticals PLC in any Content on the Site,...



Full interview: Alchemist sees big market in China for medical cannabis sales

Alchemist (CSE: AMS) CEO Paul Mann and Vice President of Business Development, Asia Pacific Johnson Lee joined Steve Darling from Proactive Vancouver to discuss Alchemist looking for opportunities for cannabis in the emerging cannabis market.  Mann and Lee talk about what the industry...

16 hours, 50 minutes ago


Holding(s) in Company

23 hours, 25 minutes ago

Holding(s) in Company

1 day, 21 hours ago

Holding(s) in Company

2 days, 21 hours ago

Holding(s) in Company

2 days, 21 hours ago

Holding(s) in Company

4 days, 1 hour ago

Holding(s) in Company

4 days, 3 hours ago

Holding(s) in Company

4 days, 22 hours ago

Block listing Interim Review

1 week, 1 day ago

2 min read